undamentalytics Newsletter
Sign in

Personalis, Inc. (PSNL) stock

Add to watchlist

Add holding +

NASDAQ: PSNL Nasdaq Life Sciences Tools & Services Next results ~November 3, 2026

E Fundamentals grade

Personalis, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Personalis, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Personalis, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 16 sales by directors and officers, last 12 monthsInsider trades
  • Funds109 adding, 54 cuttingOf 35 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Personalis files

Where Personalis stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $70m, down 13.3% on a year earlier, a smaller fall than the 24.7% decline a quarter earlier. That puts it 44 of 46 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin fell to -144.9% from -61.2% a year earlier. Operating margin narrowed to -164.1% from -89.6%. The diluted share count is up 26.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 3 financial-health checks.

Our model value for Personalis is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Personalis, Inc.'s trailing-twelve-month revenue fell 13.3% year on year, with a free-cash-flow margin of -144.9%. Where it stands out: change in growth rate of +11.5pp ranks 4 of 54 life sciences tools & services companies we cover. Where it lags: change in share count of 26.0% ranks 44 of 46 life sciences tools & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 105.3% while net income fell 17.4%: a 88pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 13.3% over the last 12 months.
  • Loss-making. Operating margin is -164.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 74.4 points on a year ago.
  • Burning cash. Free cash flow was -144.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 15.7% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 26.0% in a year.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
-$0.30 against an average estimate of -$0.28: missed by 9.1%
Revenue
$22m, up 30.0% on a year earlier
Share reaction
+2.4% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.25

Personalis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week-0.8%
  • 1 month-3.2%
  • This year+98.0%
  • 1 year+63.5%
  • 5 years-21.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$69.7M
Operating margin
-164.1%
Net margin
-153.8%
EPS (TTM, diluted)
$-1.10

Growth

Revenue growth
−13.3%
Change in growth rate
+11.5 pts
Share count change
+26.0%

Cash

Free cash flow (TTM)
-$101M
FCF margin
-144.9%
Stock pay % of revenue
15.7%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Results
  4. Agreement
  5. Results
  6. Insider trade
  7. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Personalis, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Personalis, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.2 ~$0.9–$1.5 Left out: out of range vs price (0.08x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.0 ~$2.5–$6.4 Left out: out of range vs price (0.19x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Personalis, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$10.90$36.61$14.27$1.98$2.10$5.78$7.96$15.76
Market value$393m$1.3bn$626m$90m$101m$342m$710m$1.5bn
+ Net debt (− = net cash)−$55m−$69m−$106m−$89m−$57m−$91m−$124m−$94m
Enterprise value$338m$1.2bn$521m$1m$44m$251m$586m$1.4bn
Multiples
Price / sales 6.0x16.0x7.3x1.4x1.4x4.0x10.2x22.1x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

11 /100

Weak moat

How hard Personalis's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -12.2% of total assets over 7 years.

  • Pricing power 6 / 20

    Gross margin has been a median 29.9%, moving by 6.9 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -101.4%; its worst year was -170.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -79.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 143.1% over five years; stock-based pay has been a median 14.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $21m and EPS of −$0.25 (range −$0.32 to −$0.23) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.08 −19% $84m +21%
Next −$0.97 +11% $110m +31%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.5% on 90 days ago. In the last 30 days, 0 analysts raised Personalis, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Personalis, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.03 Current fiscal year, 60 days ago: −$1.09 Current fiscal year, 30 days ago: −$1.09 Current fiscal year, 7 days ago: −$1.08 Current fiscal year, Now: −$1.08 −$1.08 Next fiscal year, 90 days ago: −$0.91 Next fiscal year, 60 days ago: −$0.94 Next fiscal year, 30 days ago: −$0.94 Next fiscal year, 7 days ago: −$0.94 Next fiscal year, Now: −$0.97 −$0.97

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.03−$0.91
60 days ago −$1.09−$0.94
30 days ago −$1.09−$0.94
7 days ago −$1.08−$0.94
Now −$1.08−$0.97

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.28 −$0.30 −9.1%
Mar 2026 −$0.28 −$0.29 −2.7%
Dec 2025 −$0.28 −$0.26 +8.8%
Sept 2025 −$0.27 −$0.24 +12.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy120%
Hold480%
Sell00%

Monthly trend

  1. Oct 2026145
  2. Sep 2026235
  3. Aug 2026235
  4. Jul 2026325

Counts of recommendations published by analysts covering Personalis, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.9%
of tradable shares
Days to cover
2.95
at average volume
Short interest, 1 month
−18%
to October 15, 2026
Held by institutions
66%
of shares
Held by insiders
25.6%
of shares
Employees
259
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +63.5%

$9.64 on October 31, 2025 to $15.76

ThenNowEffect
Revenue (last 12 months) $80m $70m −13.3%
P/S multiple 9.3x 22.1x +137.5%
Share count 77m 98m −20.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PSNL−61%−86%+6%+175%+38%+98%
Industry peers (median)+5%−51%−3%−15%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PSNL50%8%50%33%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PSNL−76%−88%−78%−48%−55%−55%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 20, 2019: 98% from January 20, 2021 to October 23, 2023. Getting back needed a 5386% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.04 – $18.38
From 52-week high
−14.3%
vs 50-day average
−3.2%
vs 200-day average
+39.3%
Volatility (1 year)
85%
Beta vs S&P 500
2.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±11.6%
After a week
6 up, 6 down
typical move ±14.2%
After a month
5 up, 7 down
typical move ±26.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +2.4% +1.6% +6.2% +26.7%
July 20, 2026 −12.7% +0.7% −22.2% −9.6%
May 7, 2026 −1.5% +0.5% +10.5% +65.4%
February 26, 2026 +9.0% −1.0% +3.0% −23.7%
January 8, 2026 −13.4% +0.7% +2.8% −16.3%
November 4, 2025 −14.9% −0.8% −6.2% +16.4%
August 5, 2025 −20.9% +0.3% −18.0% −8.6%
May 6, 2025 +13.6% −0.4% +20.7% +18.8%
February 27, 2025 −7.6% −0.1% −5.8% −19.2%
January 7, 2025 −12.6% −1.0% −19.3% −23.2%
November 6, 2024 −23.4% +3.3% −15.8% −26.4%
August 7, 2024 +7.2% +1.6% +39.4% +67.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Personalis, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Personalis, Inc.
$60M $70M $80M $90M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $70.5M Revenue (TTM), FY23 Q4: $73.5M Revenue (TTM), FY24 Q1: $74.1M Revenue (TTM), FY24 Q2: $80M Revenue (TTM), FY24 Q3: $87.5M Revenue (TTM), FY24 Q4: $84.6M Revenue (TTM), FY25 Q1: $85.7M Revenue (TTM), FY25 Q2: $80.3M Revenue (TTM), FY25 Q3: $69.1M Revenue (TTM), FY25 Q4: $69.6M Revenue (TTM), FY26 Q1: $64.5M Revenue (TTM), FY26 Q2: $69.7M $69.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $70.5M
FY23 Q4 $73.5M
FY24 Q1 $74.1M
FY24 Q2 $80M
FY24 Q3 $87.5M
FY24 Q4 $84.6M
FY25 Q1 $85.7M
FY25 Q2 $80.3M
FY25 Q3 $69.1M
FY25 Q4 $69.6M
FY26 Q1 $64.5M
FY26 Q2 $69.7M
Revenue growth, TTM YoY Personalis, Inc.
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 2.2% Revenue growth, TTM YoY, FY23 Q4: 13.0% Revenue growth, TTM YoY, FY24 Q1: 8.0% Revenue growth, TTM YoY, FY24 Q2: 19.2% Revenue growth, TTM YoY, FY24 Q3: 24.0% Revenue growth, TTM YoY, FY24 Q4: 15.2% Revenue growth, TTM YoY, FY25 Q1: 15.6% Revenue growth, TTM YoY, FY25 Q2: 0.4% Revenue growth, TTM YoY, FY25 Q3: -21.0% Revenue growth, TTM YoY, FY25 Q4: -17.7% Revenue growth, TTM YoY, FY26 Q1: -24.7% Revenue growth, TTM YoY, FY26 Q2: -13.3% -13.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 2.2%
FY23 Q4 13.0%
FY24 Q1 8.0%
FY24 Q2 19.2%
FY24 Q3 24.0%
FY24 Q4 15.2%
FY25 Q1 15.6%
FY25 Q2 0.4%
FY25 Q3 -21.0%
FY25 Q4 -17.7%
FY26 Q1 -24.7%
FY26 Q2 -13.3%
Operating margin (TTM) Personalis, Inc.
-200% -150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -167.4% Operating margin (TTM), FY23 Q4: -149.6% Operating margin (TTM), FY24 Q1: -133.5% Operating margin (TTM), FY24 Q2: -113.1% Operating margin (TTM), FY24 Q3: -84.7% Operating margin (TTM), FY24 Q4: -80.7% Operating margin (TTM), FY25 Q1: -78.3% Operating margin (TTM), FY25 Q2: -89.6% Operating margin (TTM), FY25 Q3: -117.1% Operating margin (TTM), FY25 Q4: -126.4% Operating margin (TTM), FY26 Q1: -158.9% Operating margin (TTM), FY26 Q2: -164.1% -164.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -167.4%
FY23 Q4 -149.6%
FY24 Q1 -133.5%
FY24 Q2 -113.1%
FY24 Q3 -84.7%
FY24 Q4 -80.7%
FY25 Q1 -78.3%
FY25 Q2 -89.6%
FY25 Q3 -117.1%
FY25 Q4 -126.4%
FY26 Q1 -158.9%
FY26 Q2 -164.1%
FCF margin (TTM) Personalis, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -108.5% FCF margin (TTM), FY23 Q4: -91.4% FCF margin (TTM), FY24 Q1: -91.9% FCF margin (TTM), FY24 Q2: -82.2% FCF margin (TTM), FY24 Q3: -62.5% FCF margin (TTM), FY24 Q4: -55.3% FCF margin (TTM), FY25 Q1: -54.5% FCF margin (TTM), FY25 Q2: -61.2% FCF margin (TTM), FY25 Q3: -95.8% FCF margin (TTM), FY25 Q4: -114.1% FCF margin (TTM), FY26 Q1: -131.2% FCF margin (TTM), FY26 Q2: -144.9% -144.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -108.5%
FY23 Q4 -91.4%
FY24 Q1 -91.9%
FY24 Q2 -82.2%
FY24 Q3 -62.5%
FY24 Q4 -55.3%
FY25 Q1 -54.5%
FY25 Q2 -61.2%
FY25 Q3 -95.8%
FY25 Q4 -114.1%
FY26 Q1 -131.2%
FY26 Q2 -144.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 9 38 65 79 85 65 73 85 70 70
Gross profit −2 12 22 20 32 13 18 27 16 9
EBITDA −21 −11 −18 −36 −59 −107 −99 −57 −78 −105
Operating income −22 −14 −22 −42 −65 −116 −110 −68 −88 −114
Net income −24 −20 −25 −41 −65 −113 −108 −81 −81 −107
Diluted EPS −$3.89 −$3.25 −$0.69 −$1.20 −$1.49 −$2.48 −$2.25 −$1.37 −$0.91 −$1.10
Growth (year on year)
Revenue — +302.2% +72.6% +20.6% +8.7% −23.9% +13.0% +15.2% −17.7% −13.3%
Margins
Gross margin −24.9% 31.3% 33.9% 25.6% 37.0% 20.5% 24.8% 31.7% 22.7% 12.7%
EBITDA margin −223.0% −28.3% −27.1% −46.3% −69.4% −164.6% −134.2% −67.8% −112.0% −150.2%
Operating margin −236.0% −36.5% −34.4% −53.6% −76.4% −177.6% −149.6% −80.7% −126.4% −164.1%
Net margin −251.2% −52.6% −38.5% −52.5% −76.3% −174.2% −147.4% −96.1% −116.7% −153.8%
Free-cash-flow margin −51.8% −6.0% −40.6% −58.4% −95.8% −184.7% −91.4% −55.3% −114.1% −144.9%
Cash flow
Cash from operations 0 6 −18 −43 −71 −70 −56 −45 −75 −92
Capital spending 5 8 8 3 11 50 11 2 5 9
Free cash flow −5 −2 −26 −46 −82 −120 −67 −47 −79 −101
Stock-based pay 1 1 5 8 14 19 14 11 9 11
Free cash flow after stock pay −6 −4 −31 −54 −96 −140 −81 −57 −89 −112
Balance sheet
Cash 23 20 55 69 106 89 57 91 124 94
Total debt 0 10 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −23 −10 −55 −69 −106 −89 −57 −91 −124 −94
Diluted shares 6m 6m 36m 34m 44m 46m 48m 59m 89m 98m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $312m
Short-term assets $245mLonger-term assets $67m
What it owes, and who funded it · $312m
Short-term liabilities $46mLonger-term liabilities $31mShareholders' equity $235m
  • Short-term assets cover short-term liabilities $245m of assets due within a year against $46m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $245m short-term assets against $31m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$114m against $213,000 of interest.

From Personalis, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+26.0%
year over year
R&D spending
80.5%
of revenue
Sales & admin spending
96.2%
of revenue
Days sales outstanding
79 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated PSNL XGN BNR CDXS MASS PRPO Median
Revenue, last 12 months $70m $71m $75m $78m $61m $61m $229m
Revenue growth, last 12 months −13.3% 20.8% 4.7% 35.9% 13.4% 29.5% 6.9%
Revenue growth, 3-year average 1.2% 10.3% — −7.8% 7.5% 43.6% 2.9%
Revenue growth, latest quarter 30.0% 15.9% — −2.7% 23.3% 21.9% 8.5%
Gross margin 12.7% 58.6% 74.7% 87.0% 52.2% 19.7% 51.9%
Operating margin −164.1% −18.6% −10.2% −35.6% −64.0% −2.5% −14.3%
Operating margin, 3-year average −122.3% −23.4% — −81.6% −87.7% −12.0% −22.4%
Net margin −153.8% −26.6% −10.3% −39.6% −57.0% −2.0% −16.1%
Cash from operations / revenue −132.5% −9.1% −5.3% −13.4% 2.5% 1.8% 1.3%
Free-cash-flow margin −144.9% −10.7% −6.2% −15.7% 1.0% 1.3% −2.2%
Free-cash-flow margin, 3-year average −96.1% −16.3% — −71.6% −38.7% −12.5% 0.6%
Stock pay / revenue 15.7% 4.1% 2.6% 9.9% 16.2% 3.4% 4.4%
Change in share count 26.0% 23.9% −100.0% 12.9% 4.3% 13.3% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -13.3% 6.9% 51 of 54
Change in growth rate Growth +11.5pp +0.4pp 4 of 54
Gross margin Profitability 12.7% 52.0% 43 of 45
Operating margin Profitability -164.1% -14.3% 46 of 52
Net margin Profitability -153.8% -12.2% 48 of 54
Free-cash-flow margin Cash generation -144.9% -1.3% 48 of 54
Stock pay as % of revenue Cash generation 15.7% 4.4% 43 of 53
Change in share count Balance sheet 26.0% 1.0% 44 of 46
Days sales outstanding Balance sheet 79 days 62 days 40 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$1.1B
Institutions reporting
157
Shares held vs prior quarter
▲ 0.4%
Positions opened / closed
41 / 20

Top buyers and sellers, Q2 2026: 109 institutions bought and 54 sold ; the biggest buyer was Bank Of America Corp (+1.7M shares) and the biggest seller T. Rowe Price Investment Management, Inc (−4.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Merck & Co., Inc. $188M 14.0M 16.5% 0.0%
ARK Investment Management LLC $111M 8.3M 9.7% ▲ 4.1%
Blackrock, Inc. $94.9M 7.1M 8.3% ▲ 31.4%
Lightspeed Management Company, L.L.C. $81.8M 6.1M 7.2% ▼ 25.2%
Ameriprise Financial Inc $81.6M 6.1M 7.2% ▼ 19.8%
Deep Track Capital, LP $53.6M 4.0M 4.7% ▲ 33.3%
Aberdeen Group PLC $50.2M 3.7M 4.4% ▲ 7.4%
Vanguard Capital Management LLC $40.3M 3.0M 3.5% ▲ 4.9%
Casdin Capital, LLC $34.2M 2.5M 3.0% ▲ 59.4%
Kennedy Capital Management LLC $31.7M 2.4M 2.8% ▲ 8.3%
Geode Capital Management, LLC $24.4M 1.8M 2.1% ▲ 40.4%
Bank Of America Corp $24.4M 1.8M 2.1% ▲ 1535.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Personalis, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8.8M 16 trades by 4 insiders · 94% under pre-set plans
Net ▼ $8.8M net selling
Insider Date Trade Shares Price Value
Tachibana Aaron CFO AND COO September 18, 2026 Sell 2,931 $16.22 $47,541
Hall Christopher M Chief Executive Officer September 18, 2026 Sell 7,459 $16.22 $120,985
Chen Richard President and CMO September 18, 2026 Sell 3,998 $16.22 $64,848
Moore Stephen Michael SVP and Chief Legal Officer September 18, 2026 Sell 2,068 $16.22 $33,543
Chen Richard President and CMO July 15, 2026 Sell pre-set plan 100,000 $15.15 $1.5M
Hall Christopher M Chief Executive Officer July 9, 2026 Sell pre-set plan 100,000 $15.08 $1.5M
Tachibana Aaron CFO AND COO June 29, 2026 Sell pre-set plan 4,982 $14.00 $69,748
Hall Christopher M Chief Executive Officer June 26, 2026 Sell pre-set plan 100,000 $13.15 $1.3M
Tachibana Aaron CFO AND COO June 26, 2026 Sell pre-set plan 51,251 $13.18 $675,488
Tachibana Aaron CFO AND COO June 4, 2026 Sell pre-set plan 40,000 $12.01 $480,400
Tachibana Aaron CFO AND COO May 29, 2026 Sell pre-set plan 38,799 $11.58 $449,292
Hall Christopher M Chief Executive Officer May 29, 2026 Sell pre-set plan 80,091 $11.02 $882,603

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Personalis, Inc. disclosed in the last 12 months; 3 earlier trades on record.

  • Brian J. Mast(R-FL 18):Sale (full), $15,001 - $50,000, traded May 19, 2020, filed June 4, 2020
  • Brian J. Mast(R-FL 18):Sale (full), $1,001 - $15,000, traded April 22, 2020, filed May 4, 2020
  • Brian J. Mast(R-FL 18):Purchase, $15,001 - $50,000, traded February 14, 2020, filed March 4, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

  • August 4, 2026
  • July 20, 2026
  • May 7, 2026
  • February 26, 2026
  • January 8, 2026
  • November 4, 2025

Recent SEC filings

Data status

When each part of this page on Personalis, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Personalis, Inc. in brief

What does Personalis, Inc. do?
Personalis, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Personalis, Inc.'s stock ticker?
Personalis, Inc. trades under the ticker PSNL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Personalis, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Personalis, Inc. reported revenue of $69.7M, 13.3% lower than a year earlier, according to its SEC filings.
What is Personalis, Inc.'s free cash flow?
Personalis, Inc.'s free-cash-flow margin is -144.9% of revenue over the trailing twelve months, ranking 48 of the 54 life sciences tools & services companies we cover.
Who are Personalis, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Merck & Co., Inc., ARK Investment Management LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Personalis, Inc.'s market cap?
On November 2, 2026, Personalis, Inc.'s market capitalisation was about $1.5B and net debt of -$94M. Market figures come from third-party market data and may be delayed.
Who are Personalis, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Personalis, Inc. are Exagen Inc., Burning Rock Biotech Ltd, Codexis, Inc., 908 Devices Inc. and Precipio, Inc. The side-by-side comparison below sets their revenue, margins and growth against Personalis, Inc.'s.
Are insiders buying or selling Personalis, Inc. stock?
Over the last 12 months, Personalis, Inc.'s directors and officers reported 0 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
When is Personalis, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Personalis, Inc. announces its own schedule.